# NETinfo Plc

NETIN

# Consolidated Financial Statements 2020

Please see attached

Attachment:

1. FS 2020

Non Regulated

Publication Date: 23/07/2021

# CONSOLIDATED STATEMENT OF FINANCIAL POSITION

# As at 31 December 2020

	Note	2020 €	2019 €
Assets			
Property, plant and equipment	19	3.238.272	3.279.027
Intangible assets	20	3.616.550	3.451.496
Investment properties	21	304.000	304.000
Investments in associates	23	-	97.002
Contract assets	8	123.725	65.780
Total non-current assets		7.282.547	7.197.305
Inventories	24	62.106	78.278
Contract assets	8	438.035	251.511
Trade and other receivables	25	1.010.597	937.935
Cash and cash equivalents	26	492.628	444.051
Total current assets		2.003.366	1.711.775
Total assets		9.285.913	8.909.080
Equity			
Share capital	27	2.820.547	2.820.547
Share premium		1.282.911	1.282.911
Reserves	28	(439.105)	(803.243)
Total equity		3.664.353	3.300.215
Liabilities			
Loans and borrowings	29	3.288.861	3.313.584
Deferred tax liabilities	30	71.594	74.693
Deferred income	32	61.502	66.233
Total non-current liabilities		3.421.957	3.454.510
Bank overdrafts	26	829.176	943.504
Short term portion of long-term loans	29	448.843	448.844
Trade and other payables	31	915.155	755.578
Deferred income	32	4.731	4.731
Tax liability		1.698	1.698
Total current liabilities		2.199.603	2.154.355
Total liabilities		5.621.560	5.608.865
		, –	
Total equity and liabilities		9.285.913	8.909.080

On 28 April 2021 the Board of Directors of NETinfo PLC approved and authorised these consolidated financial statements for issue.

ssos Aristodemou

freetor

Andreas Petrides

Director

# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

# For the year ended 31 December 2020

		2020	2019
	Note	€	€
Revenue	8	4.950.069	4.164.384
Cost of sales	9	(2.188.529)	(1.947.967)
Gross profit	-	2.761.540	2.216.417
Other operating income	10	89.596	64.786
Selling and distribution expenses	11	(267.250)	(261.404)
Administrative expenses	12	(1.954.618)	(1.899.950)
Impairment reversal/(loss) on trade receivables and contract assets	25	66.942	(154.686)
Loss from sale of investments in associates	23	(34.002)	
Operating profit/(loss)	13	662.208	(34.837)
Finance income	15	1.770	15.799
Finance costs	15	(205.303)	(226.556)
Net finance expenses	13	(203.533)	(210.757)
The mance expenses		(203.333)	(210.757)
Operating profit/(loss) after net finance expenses		458.675	(245.594)
Share of profit from associate	23	-	1.540
Profit/(loss) before tax		458.675	(244.054)
Tax	16	(102.647)	(90.936)
Profit/(loss) for the year		356.028	(334.990)
Other control to the total			
Other comprehensive income			
Items that will never be reclassified to profit or loss:			
Deferred tax	30	3.099	3.099
Items that are or may be reclassified to profit or loss:			
Exchange difference arising on the translation and consolidation of			
foreign companies' financial statements		22,000	120.314
Other comprehensive income for the year		25,000	122 412
Other comprehensive income for the year  Total comprehensive income/(expense) for the year		25.099 381.127	123.413 (211.577)
Basic earnings/(losses) per share (cent)	17	2,78	(2,61)
Diluted earnings/(losses) per share (cent)	17	2,65	(2,50)

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the year ended 31 December 2020

For the year ended 31 December 2020  Fair value	Share reserve-land Share capital premium and buildings Note E	2.820.547 1.282.911 819.697	•	3.099	3.099	Jeneral Health System  18
		Balance at 1 January 2019	Comprehensive income Loss for the year	Other comprehensive income Other comprehensive income for the year	Total comprehensive income for the year	Transactions with owners of the Company Special contribution to the defence fund and General Health System (GHS) on deemed distribution Total transactions with owners Balance at 31 December 2019

The notes on pages 15 to 66 are an integral part of these consolidated financial statements.

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (continued)

# For the year ended 31 December 2020

Total E	3.300.215	356.028	25,099 381.127	(16.989) (16.989) 3.664.353
Translation Accumulated reserve losses	(372.119) (1.253.920) 3.300.215	356.028	356.028	. (16.989) (16.989) - (16.989) (16.989) - (914.881) 3.664.353
		t	22.000	(350.119)
Fair value Share reserve-land premium and buildings	822.796	•	3.099	825.895
Share premium a	1.282.911	ı	£	1,282.911
Share capital	2.820.547	ı	1 1	2.820.547
Note	1		ı	<u></u>
	Balance at 1 January 2020	Comprehensive income Profit for the year	Other comprehensive income Other comprehensive income for the year Total comprehensive income for the year	Transactions with owners of the Company Special contribution to the defence fund and General Health System (GHS) on deemed distribution Total transactions with owners Balance at 31 December 2020

Companies, which do not distribute at least 70% of their profits after tax as defined by the Special Defence Contribution Law of the Republic of Cyprus during the two years after the end of the year of assessment to which the profits refer, will be deemed to have distributed this amount as dividend on the 31st of December of the second year. The amount of the deemed dividend distribution is reduced by any actual dividend already distributed by 31 December of the second year for the year to which the profits refer. when the entitled shareholders are natural tax residents of Cyprus and have their residence (domicile) in Cyprus. In addition, from 2019 (deemed distribution of dividends for the year 2017), the Company pays a General Health System (GHS) contribution on behalf of the shareholders at a rate of 2.65% (31.12.2019 1.70%), when the entitled shareholders Based on the amount of the deemed dividend distribution, the Company pays a special defence contributionon behalf of the shareholders at a rate of 17% (valid since 2014) are natural tax residents of Cyprus, regardless of their domicile.

# CONSOLIDATED STATEMENT OF CASH FLOWS

# For the year ended 31 December 2020

	Note	2020 €	2019 €
Cash flows from operating activities			
Profit/(loss) for the year		356,028	(334.990)
Adjustments for:			(,
Depreciation of property, plant and equipment	19	169.002	185.543
Amortisation of research and development	20	303.925	266.592
Share of profit from investments in associate		-	1.540
Loss from the sale of investments in associated undertakings	23	12.002	-
Inventory written off	24	32.555	-
Impairment (reversal)/charge on trade receivables and contract assets	25	(66.942)	154.686
Interest income	15	(1.409)	(2.873)
Interest expense	15	155.152	194.359
Income tax expense		102.647	90.936
Cash generated from operations before working capital changes		1.062.960	555.793
(Increase)/decrease in inventories		(16.383)	1.392
Increase in trade and other receivables		(5.720)	(291.697)
(Increase)/decrease in contract assets		(244.469)	287.191
Increase in trade and other payables	_	230.301	420.428
Cash generated from operations		1.026.689	973.107
Tax paid		(102.647)	(89.238)
Net cash generated from operating activities		924.042	883.869
Coch flows from investing activities			
Cash flows from investing activities Payment for investment in R&D	20	(469.070)	(440, (32)
· ·	20	(468.979)	(449.672)
Payment for acquisition of property, plant and equipment Proceeds from sale of investments in associate	19	(128.247)	(91.229)
Interest received	23	15.000	2.072
		1.409	2.873
Net cash used in investing activities		(580.817)	(538.028)
Cash flows from financing activities			
Repayment of borrowings	29	(153.372)	(480.224)
Proceeds from borrowings	29	(100.072)	9.281
Interest paid		(26.948)	(194.359)
Net cash used in financing activities	•	(180.320)	(665.302)
_			
Net increase/(decrease) in cash and cash equivalents		162.905	(319.461)
Cash and cash equivalents at beginning of the year		(499.453)	(179.992)
Cash and cash equivalents at end of the year	26	(336.548)	(499,453)